| Followers | 433 |
| Posts | 31258 |
| Boards Moderated | 1 |
| Alias Born | 11/28/2006 |
Tuesday, December 29, 2009 2:03:13 AM
a concern is the 225 million authorized shares here that was recently increased in the fall...the os is not 65 million..il bet on it
Recent CLRB News
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/18/2026 09:00:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/18/2026 08:15:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2026 11:20:27 AM
- Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates • GlobeNewswire Inc. • 05/14/2026 11:15:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2026 11:00:55 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/12/2026 12:07:18 AM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 05/11/2026 11:05:22 PM
- Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026 • GlobeNewswire Inc. • 05/11/2026 12:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2026 10:04:31 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/06/2026 03:48:39 PM
- Cellectar (CLRB) Phase 2b Data Shows Durable Responses in Waldenström Macroglobulinemia • IH Market News • 05/05/2026 02:21:30 PM
- Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia • GlobeNewswire Inc. • 05/05/2026 11:10:00 AM
- Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million • GlobeNewswire Inc. • 05/05/2026 11:00:00 AM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 04/30/2026 08:51:51 PM
- Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026 • GlobeNewswire Inc. • 04/21/2026 02:00:00 PM
- Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC) • GlobeNewswire Inc. • 04/14/2026 12:35:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2026 12:23:46 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/04/2026 12:21:32 PM
- Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates • GlobeNewswire Inc. • 03/04/2026 12:15:00 PM
- Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026 • GlobeNewswire Inc. • 02/25/2026 01:05:00 PM
- Cellectar Biosciences Expands Global Intellectual Property Estate • GlobeNewswire Inc. • 02/17/2026 01:05:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/13/2026 09:44:33 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/10/2026 08:23:12 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/04/2026 09:11:14 PM
- Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference • GlobeNewswire Inc. • 01/09/2026 01:05:00 PM

